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Combinatorial interactions among trans-acting factors establish transcriptional circuits that orchestrate
cellular differentiation, survival, and development. Unlike circuits instigated by individual factors, efforts to
identify gene ensembles controlled by multiple factors simultaneously are in their infancy. A paradigm has
emerged in which the important regulators of hematopoiesis GATA-1 and GATA-2 function combinatorially
with Scl/TAL1, another key regulator of hematopoiesis. The underlying mechanism appears to involve pref-
erential assembly of a multimeric complex on a composite DNA element containing WGATAR and E-box
motifs. Based on this paradigm, one would predict that GATA-2 and Scl/TAL1 would commonly co-occupy such
composite elements in cells. However, chromosome-wide analyses indicated that the vast majority of conserved
composite elements were occupied by neither GATA-2 nor Scl/TAL1. Intriguingly, the highly restricted set of
GATA-2-occupied composite elements had characteristic molecular hallmarks, specifically Scl/TAL1 occu-
pancy, a specific epigenetic signature, specific neighboring cis elements, and preferential enhancer activity in
GATA-2-expressing cells. Genes near the GATA-2–Scl/TAL1-occupied composite elements were regulated by
GATA-2 or GATA-1, and therefore these fundamental studies on combinatorial transcriptional mechanisms
were also leveraged to discover novel GATA factor-mediated cell regulatory pathways.
Combinatorial interactions among trans-acting factors estab-
lish transcriptional circuits that control fundamental biological
processes. In the context of metazoans, these interactions often
occur at regulatory elements far from genes and within introns.
Many genes require a complex collection of trans-acting fac-
tors, coregulator complexes, and long-range regulation, and
therefore considerable challenges exist in forging general prin-
ciples to explain combinatorial transcriptional control. We in-
vestigated combinatorial transcriptional mechanisms in the
context of GATA factors, which interact with an assortment of
regulatory factors to control differentiation, survival, and de-
velopment (12, 42).
GATA-1 and GATA-2 have unique and essential roles to
control hematopoiesis. GATA-2 is required for maintenance
and expansion of hematopoietic stem cells (HSCs) (78, 79),
while GATA-1 promotes the development of erythrocytes (20,
62, 63, 72), megakaryocytes (70), eosinophils (92), and mast
cells (54). GATA-2 is also expressed in endothelial cells (17,
48, 56), and conditional GATA-2 expression in embryonic
stem (ES) cells increases the genesis of hemangioblasts, pre-
cursors to hematopoietic and endothelial cells (50). GATA-2
deregulation is associated with early-onset coronary artery dis-
ease (15), atherosclerosis (69), and chronic myelogenous leu-
kemia (94), whereas GATA-1 mutations cause megakaryoblas-
tic leukemia (85) and additional blood disorders (16, 58).
Both GATA-1 and GATA-2 bind an identical DNA motif
(WGATAR) (45, 52), but the majority of these motifs are
unoccupied in cells (8, 26, 27, 34, 36, 51). Despite this shared
binding specificity, GATA-1 and GATA-2 can exert distinct
biological activities (21), indicating that each factor has certain
unique targets and/or they differentially regulate common
genes. GATA-1 and GATA-2 can occupy identical chromatin
sites and induce opposite transcriptional outputs (9). However,
they function redundantly to promote primitive erythroblast
development (21). The modes by which GATA factors select
target sites and mechanisms underlying their context-depen-
dent functions are unresolved.
Context-dependent GATA-1 activity involves the capacity of
GATA-1 to utilize diverse coregulators (5, 32, 68, 80) and the
differential sensitivity of target loci to GATA factor levels (38).
Combinatorial actions of GATA factors with other trans-acting
factors are also important (42). A paradigm has emerged in
which GATA-1 functions cooperatively with the E-box binding
proteins Scl/TAL1 and E2A as well as LMO2 and LDB1 on
WGATAR- and E-box (CANNTG)-containing composite ele-
ments in erythroid cells (47, 74, 83, 84, 89). In the context of
naked DNA, these factors form a multimeric complex that
preferentially recognizes such composite elements. Scl/TAL1
is expressed in GATA-1- and GATA-2-expressing hematopoi-
etic cells (23, 24, 28), is induced by GATA-2 (13, 50), and is
required for development of all hematopoietic cell types (66,
71), hematopoietic commitment of hemangioblasts (50), vas-
culogenesis (77), and angiogenesis (82).
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Relative to GATA-1, considerably less is known about
mechanisms underlying GATA-2 function. Only a few direct
GATA-2 target genes are known, including genes encoding
Scl/TAL1 (13, 50), GATA-2 itself (27, 46), and BMP4 (bone
morphogenetic protein 4) (50). Although transcriptional ele-
ments uniquely controlled by GATA-2, but not other GATA
factors, are unknown, an E-box–WGATAR composite ele-
ment residing within a Gata2 intron (9.5 kb downstream of the
transcription start site; hereafter referred to as the 9.5 kb site)
confers strong enhancer activity in GATA-2-expressing cells in
vitro and in the vasculature and fetal liver of mouse embryos
(41, 88). The enhancer activity requires both WGATAR and
E-box motifs (41, 88). Taken together with the paradigm that
emerged from the finding that GATA-1 and Scl/TAL1 prefer-
entially assemble a multimeric complex on composite elements in
the context of naked DNA (84), one might predict that GATA-2
and Scl/TAL1 commonly co-occupy and function through such
composite elements in vivo. However, chromosome-wide analyses
revealed that the vast majority of conserved composite elements
are not occupied by these factors. Mechanistic studies revealed
specific molecular hallmarks that distinguished these unoccupied
elements from a highly restricted subset of occupied composite
elements. Furthermore, the occupied sites pinpointed novel
GATA factor target genes that highlight new GATA factor-
dependent cell regulatory pathways.
MATERIALS AND METHODS
Cell culture. GATA-1-null G1E cells resemble normal proerythroblasts, ex-
press endogenous GATA-2, and represent a powerful system for dissecting
GATA factor mechanisms (26, 27, 29, 86, 87). G1E-ER–GATA-1 cells express
an estrogen receptor ligand binding domain fusion to GATA-1, which interacts
with chromatin similarly to endogenous GATA-1 (37). G1E-ER–GATA-1 cells
were cultured in Iscove’s modified Dulbecco’s medium (GIBCO) containing
15% fetal bovine serum (Gemini Bio-Products), 1% penicillin-streptomycin
(GIBCO), 2 U/ml erythropoietin, 120 nM monothioglycerol (MTG [Sigma]), and
0.6% conditioned medium from a kit ligand-producing CHO cell line. Puromycin
(1 mg/ml) was included in the medium for growth of G1E cells stably expressing
ER–GATA-1 (29, 37). GATA-1 was induced in G1E-ER–GATA-1 cells with 1
M -estradiol. Human umbilical vein endothelial cells (HUVECs [Cascade
Biologics]) were maintained in medium 200 (Cascade Biologics) containing 1%
penicillin–streptomycin (GIBCO) and low serum growth supplement (Cascade
Biologics). Mouse erythroleukemia (MEL) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Mediatech, Inc.) containing 5% fetal bo-
vine serum (Gemini Bio-Products), 5% bovine serum (GIBCO), and 1% anti-
biotic-antimycotic (GIBCO).
Inducible GATA-2 (iGATA-2) ES cells (50) were maintained on PMEF cells
(Specialty Media-Chemicon, NJ) in DMEM with 15% preselected fetal calf
serum (FCS), 2% leukemia inhibitory factor (LIF), 1% L-glutamine, 1% nones-
sential amino acids, and 4.5  104 M MTG. Differentiation of ES cells into
embryoid bodies (EBs) has been described previously (61). Cells were differen-
tiated in Iscove’s modified Dulbecco’s medium containing 15% differentiation-
screened FCS, 1% L-glutamine, 50 g/ml ascorbic acid, and 4.5  104 M MTG
for the indicated number of days. Serum-free conditions substituted Knockout
SR (GIBCO) for FCS and contained 5% PFHM II (GIBCO). GATA-2 was
induced in iGATA2 cells with 0.3 g/ml doxycycline (Dox) on day 2 of the
culture to generate EBs.
Plasmid constructs. GATA-2 sequences were cloned from a murine 129SV
bacterial artificial chromosome DNA isolated by Research Genetics/Invitrogen.
Primers used to amplify genomic regions of Gata2 for the creation of the
constructs used herein are available upon request. The integrity of cloned se-
quences was confirmed by DNA sequence analysis. The pGL3basic luciferase
reporter plasmid was obtained from Promega. For LacZ reporter constructs,
sequences identical to the respective transient construct were cloned into the
pSV vector (Clontech).
Transgenic mice. Transgenic mice harboring the (77)1SLacZ reporter con-
struct were generated by standard procedures by the University of Wisconsin
Transgenic Animal Facility. DNA constructs for F0 transgenic analysis were
linearized, purified with an Elutip-d column (Schleicher & Schuell), and micro-
injected into fertilized mouse oocytes. To identify embryos containing LacZ
transgenes, yolk sac genomic DNA was analyzed by PCR with LacZ-specific
primers. For whole-mount analysis, 5-bromo-4-chloro-3-indolyl--D-thiogalacto-
pyranoside (X-Gal [Sigma]) staining was performed with embryonic day 11.5
(E11.5) embryos as described previously (59, 88). Embryos were fixed with 2%
formaldehyde, 0.2% glutaraldehyde, and 0.02% Nonidet P-40 (Sigma) in phos-
phate-buffered saline (PBS) for 2 h at 4°C. Embryos were washed twice with PBS
and incubated overnight at 37°C in 2 mM MgCl2, 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6, and 0.5 mg/ml X-Gal in PBS. Embryos were washed twice with PBS
and postfixed with 4% formaldehyde overnight at 4°C. For tissue sections, the
postfixed embryos were dehydrated through progressive washes in 50, 70, 85, 95,
and 100% ethanol. Paraffin-embedded embryos were dried overnight at room
temperature, and the sectioned embryos (10 m) were counterstained with 0.1%
nuclear fast red staining solution in 5% aluminum sulfate.
Transient transfection assay. G1E and MEL cell transfections were conducted
as described previously (27). HUVECs were plated 1 day prior to transfection
and were 60 to 70% confluent at the time of transfection. An equal amount of
each plasmid (2 g) was added to 100 l of Opti-MEM (Invitrogen) reduced
serum medium, incubated with Lipofectin reagent (6 l/1 g of DNA [Invitro-
gen]) for 15 min at room temperature, and then added to the cells. Cells were
incubated with the transfection mixture for 3 h before the readdition of medium
200. Cell lysates were harvested 48 h posttransfection and assayed for luciferase
activity using the Promega luciferase assay system. The luciferase activity of each
sample was normalized to the protein concentration of the lysate, as determined
by a Bradford assay using gamma globulin as a standard. At least two indepen-
dent preparations of each plasmid were analyzed.
Quantitative ChIP assay. Quantitative chromatin immunoprecipitation (ChIP)
analysis was performed as described previously (33). Samples were cross-linked with
1% formaldehyde. Anti-GATA-2 or anti-Scl/TAL1 rabbit polyclonal antibodies
were used with protein A-Sepharose (Sigma) to adsorb immune-specific complexes
(27). Preimmune serum was used as a control. Samples were analyzed by real-time
PCR (ABI Prism 7000) using primers designed by PrimerExpress1.0 software (PE
Applied Biosystems) to amplify regions of 50 to 150 bp that overlap with the
appropriate motif. Product was measured by Sybr green fluorescence in 20-l reac-
tion mixtures, and the amount of product was determined relative to a standard
curve generated from a titration of input chromatin. Analysis of dissociation curves
postamplification showed that primer pairs generated single products.
RNA isolation and quantitative RT-PCR. Total RNA was purified with TRIzol
(GIBCO/BRL). cDNA was prepared from 1.5 g of purified total RNA. Reverse
transcription-PCR (RT-PCR) mixtures (20 l) contained 2 l of cDNA solution
with the appropriate primers. Product was measured by Sybr green fluorescence.
mRNA levels were normalized to that of GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) within the same sample, and changes (fold) in expression after
iGATA-2 or ER–GATA-1 induction were quantitated by the  threshold cycle
(CT) method.
Primers and antibodies. Anti-GATA-2 rabbit polyclonal antibody was gener-
ated against a purified glutathione S-transferase (GST) fusion to amino acids 120
to 235 of mouse GATA-2 (27). The Scl/TAL1 antibody was described previously
(25). Antibodies recognizing diacetyl histone H3 (acH3), tetraacetyl histone H4
(acH4), histone H3 dimethyl lysine 4 (H3-dimeK4), histone H3 dimethyl lysine
36 (H3-dimeK36), and histone H3 trimethylated at lysine 9 were purchased from
Upstate. The primers used in this article are available upon request.
RESULTS
Stringent molecular constraints for GATA-2-mediated com-
binatorial transcriptional control. The far upstream GATA-1-
and GATA-2-binding region of the Gata2 locus (77 kb) (27)
resembles the 9.5 kb site in containing a conserved WGATAR
and neighboring E-boxes (Fig. 1A). We tested whether the 77
and 9.5 kb sites function similarly in vivo using a LacZ vector
identical to that used in our analysis of the9.5 kb element (88).
The9.5 kb vector contained a minimalGata2 promoter fused to
LacZ and was active in vascular endothelium, endocardium, and
the fetal liver (88). Despite the common E-box and WGATAR
motifs in both the 9.5 kb and the 77 kb elements, the 77 kb
site failed to activate the Gata2 promoter-LacZ transgene in 12
out of 12 E11.5 F0 transgenic embryos (Fig. 1B). In addition to its
enhancer function in mouse embryos, the9.5 kb site activates a
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Gata2 promoter-luciferase reporter in GATA-2-expressing endo-
thelial (HUVEC) and hematopoietic (G1E) cells, which requires
WGATAR and E-box motifs (88). Since the 77 kb site can
activate the Gata2 promoter reporter in G1E cells, we tested
whether it also functions in HUVECs. In contrast to the 9.5 kb
site, the 77 kb site lacked activity (Fig. 1C).
The 9.5 kb site enhancer activity in endothelial cells re-
quires an E-box–WGATAR-containing core module and reg-
ulatory modules containing additional cis elements (88),
whereas the core module suffices for activity in GATA-2-ex-
pressing hematopoietic cells. The functional difference be-
tween9.5 and77 kb sites in HUVECs might therefore arise
from the lack of 77 kb regulatory modules or differences in
their core modules. To distinguish between these possibilities,
chimeric elements were generated in which the WGATAR-
and E-box-containing77 kb core was substituted for the9.5
kb core. The 77 kb core was incapable of reconstituting
activity of the core-deleted 9.5 kb site, and a larger 77 kb
core fragment containing the WGATAR motif and two flank-
ing E-boxes also did not reconstitute activity (Fig. 1C). Thus,
the 77 kb core differs from the 9.5 kb core, which confers
GATA-2-dependent activation in endothelial cells.
Since the 9.5 and 77 kb cores are functionally distinct,
presumably their cis-element compositions or configurations
differ. The 9.5 kb core critically requires WGATAR and
E-box motifs for activity in HUVEC and G1E cells (88). Al-
though the 77 kb site lacks enhancer activity in HUVECs
(Fig. 1C), it is active in G1E cells, and we tested whether this
activity is WGATAR and E-box dependent. While mutation of
WGATAR abrogated activity, mutation of the two E-boxes
individually or collectively only slightly reduced activity (Fig.
1D). The 77 kb site activity therefore requires WGATAR,
but the conserved E-boxes are largely unimportant in G1E
cells. These results illustrate how WGATAR motifs suffice to
mediate GATA factor function in certain contexts, while re-
quiring additional cis-elements in other contexts.
Although both the 9.5 and 77 kb cores contain WGATAR
and E-box motifs, they differ in their cell-type-specific enhancer
FIG. 1. A conserved WGATAR motif with nearby E-boxes is insufficient for autonomous enhancer activity in chromatin. (A) Gata2 locus
organization. Open and filled boxes depict noncoding and coding exons, respectively. The sequence conservation of the E-box- and GATA
motif-containing core modules of the 77 and 9.5 kb sites is shown below. Arrows above the GATA motifs identify the orientation of each motif
with respect to forward and reverse strands. (B) Representative photographs of whole-mount and transverse sections of two (left and right
columns) E11.5 embryos harboring a transgene containing the Gata2 77 kb site upstream of the Gata2 1S promoter fused to LacZ
[(77)1SLacZ]. For embryos containing (77)1SLacZ, histological sections show complete lack of endothelial staining in the dorsal aorta (DA)
and endocardium (EC) and also in the fetal liver (FL). 77(20) and 77(2) are two representative transgene-positive embryos. Note that the
transgene lacks activity in these and 10 additional embryos tested. (C) Analysis of core module activities via generation of chimeric regulatory
elements. HUVECs were transiently transfected with reporters derived from pGL3luc containing the Gata2 1S promoter cloned upstream of
luciferase (1SLuc). The plot depicts the average luciferase activities of the cell lysates normalized by protein concentrations (at least three
independent experiments). In each experiment, transfections were performed in triplicate. (D) G1E cells were transiently transfected with
reporters derived from pGL3luc containing the Gata2 1S promoter cloned upstream of luciferase (1SLuc). The plot depicts the average luciferase
activities of cell lysates normalized by the protein concentrations (at least three independent experiments). In each experiment, transfections were
performed in triplicate. *, P  0.05 with respect to (77)1SLuc.
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FIG. 2. Strict architectural constraints for GATA factor-mediated combinatorial transcriptional control. (A) cis-element spacing requirements.
Mutant plasmids were generated in which nucleotides between the E-box and WGATAR motifs were either deleted (1, 2, and 3) or added
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activities and E-box utilization. Their WGATAR motifs have
distinct orientations and spacing relative to neighboring E-boxes.
To test whether spacing constraints exist for 9.5 kb activity in
G1E cells and HUVECs, 1, 2, or 3 bp were deleted, and 1, 2, 3,
5, or 10 bp were inserted between the WGATAR motif and
E-box. Whereas 1-bp deletions or insertions were tolerated with
only 22 to 33% decreases in enhancer activity (Fig. 2A), deletions
or insertions of 2 bp severely reduced activity. Scrambling 4 bp
of intervening sequence (4 core) did not affect activity, indicat-
ing that the specific intervening sequences are not essential. If the
deletions or insertions inhibit activity by altering the helical ori-
entation of the WGATAR and E-box with respect to each other,
a 10-bp insertion that maintains the configuration should be in-
consequential. However, the 10-bp insertion mutant lacked activ-
ity, consistent with a critical spacing constraint rather than a
precise helical geometry.
To determine if the linear orientation of WGATAR relative to
the E-box is important, the WGATAR and E-box orientations
were reversed (Fig. 2B). While reversing the orientation of the
E-box reduced enhancer activity by 38 and 46% in HUVEC and
G1E cells, respectively, reversing the orientation of WGATAR,
with or without 3 bp of flanking sequence, abrogated activity.
Reversing the orientation of both WGATAR and the E-box was
also devastating, whereas reversing the orientation of the full core
and 3 bp of flanking sequence, which maintains the WGATAR
orientation relative to the E-box, only slightly reduced activity.
These results provide evidence for a stringent orientation con-
straint in which CANNTG resides upstream of WGATAR on the
same strand of DNA. It is instructive to compare these findings to
a site selection analysis with erythroleukemia cell extracts and
randomized 26-bp oligonucleotides (84). This analysis used
LMO2, Scl/TAL1, and E2A antibodies to select bound oligonu-
cleotides containing an E-box 8 to 10 bp upstream of a GATA
motif. Although the importance of spacing, helical geometry, and
motif orientation on naked DNA binding, enhancer activity, and
chromatin occupancy were not evaluated, our results on con-
straints for enhancer activity mirror those obtained from the site
selection analysis. Thus, combinatorial regulation of enhancer
activity with nonchromosomal templates might reflect GATA-2–
E-protein nucleoprotein complex assembly, analogous to the pro-
posed mechanism for GATA-1 (84).
Chromosome-wide analysis of GATA-2 occupancy at con-
served composite elements: the vast majority of composite
elements are unoccupied. Endogenous GATA-1 and an estro-
gen receptor ligand binding domain fusion to GATA-1 (ER–
GATA-1) occupy a small percentage of WGATAR motifs in
chromatin (8). Our studies at multiple loci revealed GATA-1
occupancy at a small subset (10%) of conserved WGATAR
motifs (8). GATA-1 and GATA-2 share many chromatin sites,
but differences can exist (51). Whereas FOG-1 increases
GATA-1 occupancy at certain sites (49, 60), other parameters
governing occupancy are undefined. Whether positioning an
E-box near a WGATAR motif influences the probability of
GATA factor occupancy is unknown.
As E-box–WGATAR composite element function in GATA-
2-expressing cells requires a precise geometry (Fig. 1 and 2), this
geometry might facilitate GATA-2 chromatin occupancy or
enhance GATA-2 function postoccupancy. We conducted
quantitative ChIP analysis in GATA-1-null G1E cells to test
whether GATA-2 preferentially occupies composite elements
in a configuration that is optimal for enhancer activity (Fig. 2)
versus WGATAR motifs lacking E-boxes within 20 bp of
WGATAR. GATA-2 occupancy was analyzed at 63 conserved
WGATAR motifs lacking E-boxes on chromosome 6 (Fig. 3A)
and at all conserved composite elements on chromosomes 1, 6,
and 7 (Fig. 3B to D). Amplicons encompassed WGATAR
motifs or composite elements in which the WGATAR motif,
E-box, and the intervening spacing, are conserved (mice to
humans). To minimize gross differences in chromosomal posi-
tions and to ensure that ChIP signals did not overlap, we
analyzed conserved WGATAR motifs lacking nearby E-boxes
that were 3 to 50 kb from the corresponding composite ele-
ments on chromosome 6. GATA-2 occupied 4.8% (3/63) (Fig.
3A) and 9.8% (16/164) (Fig. 3B to E) of WGATAR motifs
lacking E-boxes and composite elements, respectively. Statis-
tical analysis using a z-test for two proportions indicated that
the E-box does not significantly (P 	 0.342) increase the prob-
ability of GATA-2 occupancy. The vast majority of both com-
posite and WGATAR sites tested are unoccupied.
Diagnostic molecular hallmarks of GATA-2-occupied com-
posite elements. Scl/TAL1 and GATA-1 preferentially assemble
a complex on oligonucleotides containing E-box–WGATAR
composite elements (84). As Scl/TAL1 is also expressed in
GATA-2-expressing multipotent hematopoietic precursors (23,
28), we reasoned that Scl/TAL1 might reside at certain GATA-
2-occupied composite elements. Quantitative ChIP analysis in
G1E cells revealed little to no signal at the necdin and Ey pro-
moters that lack composite elements, at multiple conserved
WGATAR motifs within the Gata2 and Fmod-Btg2 loci lacking
E-boxes, and at conserved composite elements not occupied by
GATA-2 (Fig. 4). In contrast, Scl/TAL1 occupied all GATA-2-
occupied composite elements, and therefore Scl/TAL1 occupancy
at the composite elements was absolutely predictive of GATA-2
occupancy.
Another potentially important hallmark of GATA-2-occu-
pied composite elements is the local chromatin environment.
The chromatin environment surrounding large numbers of
WGATAR motifs or composite elements has not been de-
scribed. Intriguingly, the occupied and unoccupied conserved
composite elements had distinct epigenetic signatures. Epige-
netic marks that often signify active chromatin, specifically
di-acetylated H3, tetra-acetylated H4, and H3-dimeK4 (8),
(1, 2, 3, 5, and 10). In the (9.5 4core)1SLuc plasmid, 4 bp between the E-box and WGATAR motifs were scrambled. G1E cells and
HUVECs were transiently transfected with the indicated reporter plasmids. The plot depicts the average luciferase activities of the cell lysates
normalized by protein concentrations (at least three independent experiments). In each experiment, transfections were performed in triplicate. *,
P  0.05 with respect to (9.5)1SLuc. (B) cis element orientation requirements. G1E cells and HUVECs were transiently transfected with the
indicated reporters. The plot depicts the average luciferase activities of the lysates normalized by protein concentrations (at least three independent
experiments). In each experiment, transfections were performed in triplicate. *, P  0.05 with respect to (9.5)1SLuc.
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FIG. 3. Chromosome-wide GATA-2 occupancy at conserved WGATAR motifs and E-box-WGATAR composite motifs. (A) Quantitative ChIP
analysis of GATA-2 occupancy at 63 conserved WGATAR motifs (within 3 to 50 kb of the corresponding conserved composite motifs of panel
B) across mouse chromosome (Chr.) 6 in G1E cells (mean 
 standard error from three independent experiments). The numbers on the x axis
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were selectively enriched at the occupied sites (Fig. 5). H3-
dimeK36, whose distribution in functionally distinct chromatin
regions is less well defined, was also enriched at the occupied
sites (Fig. 5). In contrast, H3-trimeK9, which is often, but not
always, present at repressed chromatin sites (8, 81), was selec-
tively enriched at half of the unoccupied sites and was enriched
at only 1 of 16 occupied sites. Considering the combinations of
epigenetic marks, enrichments of acetylated H3 and H4, H3-
dimeK4, and H3-dimeK36 combined with a deficiency of H3-
trimeK9 are highly predictive of GATA-2 and Scl/TAL1 occu-
pancy at conserved composite elements. As a sole predictive
parameter, H3-trimeK9 was least useful, which might relate to
the fact that this marker is enriched at certain repressed and
active chromatin sites (81).
To reveal additional potential molecular hallmarks of
GATA-2–Scl/TAL1 occupancy, rigorous statistical analysis was
conducted to identify sequences that may discriminate between
occupied and unoccupied composite elements. We tested
whether sequences within the composite element correlate
with occupancy by using a logistic regression model with occu-
pancy status as the outcome and nucleotide compositions in
each of the 12 degenerate positions (positions 3, 4, 7 to 15, and
20) within the 20 positions of the composite element as ex-
planatory variables. This model also allowed two-way interac-
tions of these positions. Neither variations among nucleotide
compositions of the individual positions (Fig. 3E) nor their
two-way interactions significantly correlated with occupancy.
Since multiple trans-acting factors interact with GATA fac-
tors (42) and certain factor (e.g., Ets) are required for GATA-
2-dependent transcription in specific contexts (65), we tested
whether their cognate motifs reside near the composite ele-
ments and correlate with occupancy. Consensus motifs for Ets
factors, Sp1, EKLF, ZBP89, NF-E2/AP1, AML1/Runx1, and
Gfi1b were identified in sequences flanking occupied and un-
occupied composite elements (
 50, 100, 150, 250, or 500 bp
from the composite element). We tested whether these sites
discriminate between the two groups of composite elements.
Only the Sp1 consensus [GT][GA]GGC[GT][GA][GA][GT]
was a significant discriminator, which appeared in 6/16 occu-
pied composite elements and only 14/148 unoccupied ele-
ments, when considering 
250 bp of flanking sequence (P 	
0.0056; Fisher’s exact test of the corresponding 2-by-2 table).
When the flanking sequences are extended to 
500 bp, 9/16
and 37/148 of the regions in occupied and unoccupied groups,
respectively, have at least a copy of this motif within their
flanks (P 	 0.016). Thus, the Sp1 consensus, which binds mul-
tiple factors (64), some of which interact with GATA-1 (53),
and cooperates with WGATAR and additional cis-elements to
establish DNase I hypersensitivity (22), is significantly enriched
in occupied versus unoccupied regions.
De novo analysis of sequences flanking the composite ele-
ments (
 50, 100, 150, 250, or 500 bp) using MEME (3) and
COSMO (4) algorithms identified a highly significant differen-
tial enrichment of a novel motif [TC][CT][CT]TG[GT][GC]
[CG][AT]G[TG] in occupied versus unoccupied groups. This
motif occurs within 
100 bp of the composite elements in
10/16 occupied regions and only 7/148 unoccupied regions
(P 	 4.109e08), and has not been implicated in protein
binding or transcription. The positions of the novel and Sp1
motifs with respect to occupied composite elements are shown
correspond to nearest-neighbor genes listed in Table S1 in the supplemental material. The numbers of GATA-2-occupied motifs are also shown
at their specific chromosomal locations. (B to D) Quantitative ChIP analysis of GATA-2 occupancy at all conserved E-box–WGATAR composite
motifs across mouse chromosome 6 (B), chromosome 1 (C), and chromosome 7 in G1E cells (mean 
 standard error from three independent
experiments). The numbers on the x axis correspond to nearest-neighbor genes listed in Table S1 in the supplemental material. The numbers of
GATA-2-occupied motifs are also shown at their specific chromosomal location. (E) Sequence composition of 148 unoccupied (left) and 16
occupied composite elements (right). The x axis depicts the nucleotide position within the composite element, and the y axis represents the relative
frequencies of the nucleotides.
FIG. 4. Scl/TAL1 occupancy at conserved composite elements occurs exclusively at GATA-2-occupied elements. Quantitative ChIP analysis
was conducted in G1E cells to measure Scl/TAL1 occupancy at GATA-2-occupied, conserved composite elements, GATA-2-unoccupied,
conserved composite elements, and control sites lacking composite elements (mean 
 standard error from three independent experiments).
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in Fig. S1 in the supplemental material. A combinatorial rule,
in which the Sp1 and/or the novel motif resides at a locus,
identifies 14/16 occupied sites as occupied and only 21/148
unoccupied sites as occupied (P 	 5.596e08). Neither the
novel nor the Sp1 motif significantly associates with occupied
WGATAR sequences lacking nearby E-boxes. Collectively, the
Scl/TAL1 occupancy, the epigenetic patterns, and the statisti-
cal distribution of specific cis elements establish diagnostic
molecular hallmarks of Scl/TAL1–GATA-2 complexes on
composite elements in hematopoietic cells.
FIG. 5. GATA-2–Scl/TAL1-occupied and -unoccupied conserved composite elements have diagnostic epigenetic signatures. Quantitative ChIP
analysis was conducted in G1E cells to measure the indicated epigenetic marks at GATA-2-occupied, conserved composite elements, GATA-2-
unoccupied, conserved composite elements, and active (RPII215) and inactive (necdin) promoters lacking composite elements (mean 
 standard
deviation from two independent experiments).
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Based on the molecular hallmarks described above, we
reasoned that Scl/TAL1–GATA-2 complexes assembled at
composite elements would have the capacity to regulate tran-
scription. To test whether occupied composite elements func-
tion as GATA factor-dependent enhancers, we analyzed the
activities of the respective elements with 10 bp of flanking
sequence on the 5 and 3 ends in a transient transfection assay
(Fig. 6A). While 7 out of 10 occupied composite elements
conferred statistically significant enhancer activity in GATA-
2-expressing G1E cells, with three exhibiting particularly no-
table activity, only 1 out of 10 composite elements (Gata29.5
element) had significant activity in GATA-1-expressing MEL
cells, and this activity was low. Similar results were obtained in
DMSO-induced MEL cells (data not shown). In contrast, the
3.9 kb region of the Gata2 locus, which lacks a composite
element but is activated by GATA-1 via a WGATAR motif
(51), was highly active in MEL cells. Thus, a subset of the
occupied composite elements function as enhancers, preferen-
tially in GATA-2-expressing cells. To test whether the novel
enhancers that function in G1E cells indeed require E-box and
WGATAR motifs, we generated reporter constructs contain-
ing the Riken 6530409C15 (Riken C15) composite element in
FIG. 6. GATA-2–Scl/TAL1-occupied composite elements function as enhancers in GATA-2- but not GATA-1-expressing cells. (A) G1E and
MEL cells were transiently transfected with reporter constructs containing the indicated composite elements as well as 10 bp of upstream and
downstream flanking sequence. The plot depicts the average luciferase activities of the cell lysates normalized by protein concentrations (mean 

standard error from at least three independent experiments). In each experiment, transfections were performed in triplicate. *, P  0.05 with
respect to 1SLuc. The horizontal gray bar delineates the 1.0 value of the 1SLuc construct. (B) G1E cells were transiently transfected with reporter
constructs containing the wild type (sequence depicted on top of the graph), E-box mutant, WGATAR mutant, and E-box–WGATAR double
mutant of the Riken 6530409C15 (Riken C15) composite element with 10 bp of upstream and downstream flanking sequence. The plot depicts
the average luciferase activities of the cell lysates normalized by protein concentrations (mean 
 standard error from three independent
experiments). In each experiment, transfections were performed in triplicate. *, P  0.05 with respect to (Rik. C15)1SLuc. (Rik. C15)1SLuc is the
1SLuc plasmid containing the Riken C15 composite element; (Rik. C15 mtE)1SLuc is the 1SLuc plasmid containing the Riken C15 composite
element with a scrambled E-box (CATATG3GAATTC); (Rik. C15 mtG)1SLuc is the 1SLuc plasmid containing the Riken C15 composite
element with a scrambled WGATAR motif (AGATAA3GAGCTC); (Rik. C15 mtE-mtG)1SLuc is the 1SLuc plasmid containing the Riken C15
composite element with a scrambled E-box and scrambled WGATAR motif.
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which these motifs were mutated (Fig. 6B). Mutation of the
E-box, WGATAR, or both motifs abrogated enhancer activity
(Fig. 6B).
Novel cell regulatory pathways derived from analysis of
chromatin targets. As GATA-2 occupied composite elements
near genes not known to be GATA factor target genes, we
tested whether Dox-mediated induction of GATA-2 during
mouse ES cell differentiation into EBs (50) alters expression of
genes neighboring the occupied composite elements (Fig. 7A).
We also compared gene expression in Gata2/ and wild-type
EBs. Addition of Dox on day 2 of the culture greatly increased
Gata2 mRNA in day 3, 4, 6, and 8 EBs derived from iGATA-2
ES cells (Fig. 7B). Similarly, Dox significantly induced the
established GATA-2 target (50) Scl/TAL1 (12-fold), and the
novel GATA-2 targets Sox6 and Fmod (4.1- and 68-fold, re-
spectively) (Fig. 7B). Sox6 promotes chondrogenesis (73), re-
presses embryonic -like globin transcription in definitive ery-
throid cells (91), and functions cell autonomously to promote
proliferation, survival, and differentiation of erythroid cells
(18). Fibromodulin is a small, leucine-rich proteoglycan that
suppresses signaling mediated by transforming growth factor 
(TGF-) and related cytokines (90), and the related protein
biglycan binds BMP4, suppressing BMP4 signaling (57). Dox
significantly decreased Btg2 expression (2.1-fold), while expres-
sion of other genes changed 2-fold. Btg2 (1) functions down-
stream of p53 to promote cell cycle arrest (6), suppresses
Ras-induced transformation (6), and is deregulated in breast
and renal cancer (40, 76).
Fmod was highly downregulated in Gata2-null EBs (Fig.
7C). Taken together with the striking Dox-dependent Fmod
induction (68-fold) and the endogenous GATA-2 interaction
with the Fmod locus, these results establish Fmod as a bona
fide GATA-2 target gene (Fig. 7D). The magnitude of the
GATA-2-mediated Fmod induction is considerably greater
than that for any other GATA-2 target gene reported. Fmod is
the most highly overexpressed gene in B-cell chronic lympho-
cytic leukemia (CLL) (35, 44, 55), but mechanisms underlying
its normal transcriptional control and deregulation in CLL are
unknown. Fibromodulin is secreted from CLL cells and resides
intracellularly (55). As fibromodulin suppresses signaling by
TGF- and related proteins (90), biglycan suppresses BMP4
signaling (57), proteoglycans suppress signaling by BMP fac-
tors in Drosophila melanogaster (7), and BMP4 induces Gata2
expression (19, 50), Fmod overexpression in CLL might disrupt
a circuit (Fig. 7D) in which BMP4 induces and/or sustains
Gata2 expression in the hematopoietic niche. The role of these
factors in hematopoiesis and leukemogenesis is unexplored.
Expression of the additional genes in wild-type versus
Gata2/ EBs differed by less than twofold (Fig. 7C), although
it cannot be ruled out that GATA-2 regulates these genes
redundantly with other factors and/or nonredundantly in dis-
tinct contexts. We also conducted complementation analysis in
GATA-1-null proerythroblast-like G1E cells stably expressing
ER–GATA-1 (26, 27, 29, 34, 43, 51, 60). -Estradiol-mediated
ER–GATA-1 activation instigates GATA-2 displacement at
chromatin sites, and “GATA switches” increase or decrease
transcription (9). ER–GATA-1-mediated activation or repres-
sion can result from disruption of GATA-2-mediated tran-
scriptional control. ER–GATA-1 activation in G1E-ER–
GATA-1 cells repressed Gata2 (76-fold) (Fig. 7B, right), as
expected (26), and also repressed Sox6, Tram2, and Etv6 (9.1-,
21-, and 3.2-fold, respectively). Tram2 is a BMP and Runx2
target gene in osteoblasts (67) and regulates protein translo-
cation in the endoplasmic reticulum (75). Etv6 (Tel), a mem-
ber of the Ets transcription factor family, is a key regulator of
adult HSCs that is frequently disrupted via leukemogenic chro-
mosomal translocations (30, 93). ER–GATA-1 induced Btg2,
Bpgm, Foxp1, and Bcl2l13 (323-, 15-, 8.5-, and 6.0-fold, respec-
tively). Bpgm encodes bisphosphoglycerate mutase, which cat-
alyzes synthesis of the major allosteric regulator of hemoglobin
(11). The Forkhead transcription factor Foxp1 is a prognostic
factor in diffuse large B-cell lymphoma (10), but whether it
functions in hematopoiesis is unclear. The proapoptotic factor
Bcl2l13 (39) is a prognostic factor in B-lineage acute lympho-
cytic leukemia (31). Fmod was expressed at almost undetect-
able levels in untreated and estradiol-treated G1E-ER–
GATA-1 cells, and considering the ES cell data, GATA-2 is
necessary but insufficient to confer high-level Fmod expression.
DISCUSSION
We have demonstrated that GATA-2 occupies a highly re-
stricted subset of conserved composite elements, and this sub-
set exhibited unique molecular hallmarks relative to the highly
abundant unoccupied elements. GATA-2-occupied sites were
co-occupied by Scl/TAL1 and had both a distinctive epigenetic
signature and specific neighboring cis elements. These param-
eters offer considerable predictive value and provide important
mechanistic insights vis-a`-vis GATA-2 recognition of target
sites in chromatin.
The GATA-2–Scl/TAL1 occupancy at all GATA-2-occupied
composite elements strongly suggests that these factors func-
tion combinatorially at common targets in the genome. As our
quantitative comparison of GATA-2 occupancy at composite
elements versus isolated WGATAR motifs did not reveal sig-
nificant differences, it seems unlikely that the composite ele-
ment serves to increase the probability of GATA-2 occupancy.
Thus, it is attractive to propose that both factors function
collectively post-chromatin occupancy to recruit requisite co-
regulators, thereby conferring combinatorial transcriptional
control.
Since GATA-1 functionally interacts with Scl/TAL1 in the
context of composite elements (84), we assumed that the
GATA-2- and Scl/TAL1-occupied composite elements would
function as GATA-1- and perhaps GATA-2-responsive en-
hancers. However, while a subset of these elements functioned
as enhancers in GATA-2-expressing cells, 9 out of 10 were not
significantly active in GATA-1-expressing cells (Fig. 6A). Thus,
it is instructive to compare our results with those of studies
implicating GATA-1 in functioning through DNA sequences
containing E-box and WGATAR motifs. In gel-shift assays
using MEL cell nuclear extracts, GATA-1, the E-proteins Scl/
TAL1 and E2A, and their interacting proteins Lmo2 and Ldb1
assemble a complex on oligonucleotides containing E-box
and WGATAR or GATA motifs (83, 84, 89). Sequences con-
taining both E-box and WGATAR motifs, but considerably
larger than the 40-bp composite elements that we analyzed,
activate reporter genes in transiently transfected MEL cells (2,
14, 89) and in erythroid cells in vivo (83). The 1.7-kb P4.2
promoter, which contains two E-box–WGATAR composite
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FIG. 7. Occupied composite elements reside at and near novel GATA factor target genes. (A) Diagrams of nearest-neighbor genes surrounding
GATA-2-occupied E-box–GATA motifs on mouse chromosomes (Chr.) 1, 6, and 7. Asterisks denote the locations of conserved E-box–WGATAR
motifs, arrows denote transcription start sites, and shaded boxes indicate the coding regions of the genes. (B) The table summarizes changes (fold)
in the GAPDH-normalized expression of selected genes surrounding GATA-2-occupied E-box–WGATAR composite elements in day 3/4, 6, and
8 EBs derived from mouse ES cells following Dox-mediated GATA-2 induction (mean 
 standard error from nine independent experiments for
day 3/4 and 6 EBs and from six independent experiments for day 8 EBs) and also in G1E-ER–GATA-1 cells after estradiol-mediated activation
of ER–GATA-1 (mean 
 standard error from three independent experiments). mRNA levels were quantitated by real-time RT-PCR. (C) The
graph depicts the GAPDH-normalized expression of genes surrounding GATA factor-occupied E-box–WGATAR composite elements in day 3
and 6 EBs derived from Gata2/ ES cells divided by their expression in day 3 and 6 EBs derived from wild-type ES cells, respectively (mean 

standard error from three independent experiments). mRNA levels were quantitated by real-time RT-PCR. (D) Model of BMP4–GATA-2–
fibromodulin regulatory circuit.
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elements, functions as an enhancer in MEL cells (89). Further-
more, smaller sequences containing an E-box–E-box–WGA-
TAR motif (14) or a WGATAR–E-box–WGATAR motif (2)
function as enhancers in MEL cells (approximately twofold
and approximately fivefold, respectively). A 1.1-kb Gata1 reg-
ulatory element (HS1) containing a WGATAR motif 9 bp
downstream from an E-box activates LacZ expression in prim-
itive erythroid cells in the yolk sac at E10.5 and in definitive
erythroid cells in the fetal liver of E14.5 transgenic mouse
embryos (83). In contrast, a smaller HS1 derivative (62 bp)
containing only the WGATAR motif without the E-box retains
activity, and therefore the E-box is not required for activity of
this sequence in erythroid cells. Our study, which represents
the first to analyze E-box–GATA composite motifs with de-
fined spacing/orientation, demonstrates striking differences in
their responsiveness to GATA-1 versus GATA-2 and also dif-
ferent intrinsic activities in GATA-2-expressing cells. Thus, it
is attractive to propose that cis elements neighboring the com-
posite elements influence their efficacy as enhancers and also
specificity vis-a`-vis different GATA factors.
Intriguingly, a specific epigenetic signature was one of the
molecular hallmarks deduced that distinguishes occupied ver-
sus unoccupied composite elements. This specific chromatin
modification state might be a prerequisite for GATA-2–Scl/
TAL1 complex assembly at composite elements in chromatin,
or the complex might establish this signature post-chromatin
occupancy. Since GATA-2 is expressed in HSCs, and no trac-
table systems exist to examine chromatin structure at target
sites prior to the physiological appearance of GATA-2, distin-
guishing between these models will be challenging. In princi-
ple, one could ask whether knocking down GATA-2 in G1E
cells reconfigures the epigenetic signature. However, we have
not achieved efficacious GATA-2 knockdowns in this system.
Even if a satisfactory degree of knockdown can be achieved,
persistence of the epigenetic signature might reflect its estab-
lishment prior to complex assembly or a GATA-2 requirement
for establishment, but not maintenance, of the signature. Nev-
ertheless, our results provide the first example in which
GATA-2-occupied target sites, or target sites occupied by any
GATA factor or master regulator of hematopoiesis, exhibit a
specific epigenetic signature that provides a unique foundation
for conducting subsequent mechanistic analysis.
The GATA-2–Scl/TAL1-co-occupied target sites pinpointed
neighboring genes that are GATA-2 and/or GATA-1 respon-
sive. Thus, the functional genomic strategy established novel
links between GATA-2 and proteins involved in important
biological processes, including leukemogenesis. Other than
Btg2, which was described in an analysis of GATA-1 target
genes (87), GATA factors had not been linked to the regula-
tion of genes identified in our screen. Furthermore, no prior
reports have identified GATA-2 target genes using the multi-
ple approaches described herein: endogenous GATA-2 occu-
pancy of endogenous loci, regulation of the endogenous genes
upon conditional expression of GATA-2 in physiologically rel-
evant ES cells, and also regulation of the endogenous genes in
Gata2 knockout cells. The novel targets (Fig. 7B) define five
transcriptional modes: (i) GATA-2 activated, (ii) GATA-2 ac-
tivated and GATA-1 repressed, (iii) GATA-1 activated, (iv)
GATA-1 repressed, and (v) neither GATA-1 nor GATA-2
regulated. It will be particularly instructive to assemble the
genome-wide genetic network collectively instigated by
GATA-2 and Scl/TAL1 at composite elements to gain a com-
prehensive view of how stem cells give rise to diverse lineages
of blood cells, how perturbations of this network causes leu-
kemia, and, more fundamentally, how two cell-type-specific
trans-acting factors selectively recognize their targets and func-
tion at a highly restricted subset of composite elements in a
complex genome.
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